180 related articles for article (PubMed ID: 37248064)
1. [Relationship between plasma levels of thrombin activatable fibrinolysis inhibitor, plasminogen activator inhibitor-1 and tissue-type plasminogen activator and deep venous thrombosis in patients with systemic lupus erythematosus].
Liu YF; Hou N; Shi YJ; Li CX; Gao YJ; Liu LN
Zhonghua Yi Xue Za Zhi; 2023 Jun; 103(21):1638-1642. PubMed ID: 37248064
[No Abstract] [Full Text] [Related]
2. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.
Meltzer ME; Lisman T; de Groot PG; Meijers JC; le Cessie S; Doggen CJ; Rosendaal FR
Blood; 2010 Jul; 116(1):113-21. PubMed ID: 20385790
[TBL] [Abstract][Full Text] [Related]
3. Assessment of plasminogen activator inhibitor-1(PAI1) and thrombin activitable fibrinolysis inhibitor (TAFI) in Egyptian children with hemophilia A.
Soliman M; Osman N; Hefnawy S; El Hawy MA
Pediatr Hematol Oncol; 2022 May; 39(4):318-328. PubMed ID: 34668834
[TBL] [Abstract][Full Text] [Related]
4. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.
Erem C; Kocak M; Nuhoglu I; Yilmaz M; Ucuncu O
Eur J Endocrinol; 2009 May; 160(5):863-8. PubMed ID: 19233920
[TBL] [Abstract][Full Text] [Related]
5. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
Ermantas N; Guldiken S; Demir M; Tugrul A
Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
[TBL] [Abstract][Full Text] [Related]
6. Active PAI-1 as marker for venous thromboembolism: case-control study using a comprehensive panel of PAI-1 and TAFI assays.
Bollen L; Peetermans M; Peeters M; Van Steen K; Hoylaerts MF; Declerck PJ; Verhamme P; Gils A
Thromb Res; 2014 Nov; 134(5):1097-102. PubMed ID: 25193405
[TBL] [Abstract][Full Text] [Related]
7. Fibrinolysis inhibitors in plaque stability: a morphological association of PAI-1 and TAFI in advanced carotid plaque.
Jönsson Rylander AC; Lindgren A; Deinum J; Bergström GM; Böttcher G; Kalies I; Wåhlander K
J Thromb Haemost; 2017 Apr; 15(4):758-769. PubMed ID: 28135035
[TBL] [Abstract][Full Text] [Related]
8. Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients.
Fernandez-Cadenas I; Alvarez-Sabin J; Ribo M; Rubiera M; Mendioroz M; Molina CA; Rosell A; Montaner J
J Thromb Haemost; 2007 Sep; 5(9):1862-8. PubMed ID: 17723126
[TBL] [Abstract][Full Text] [Related]
9. Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients.
Akinci B; Comlekci A; Yener S; Demir T; Ozcan MA; Bayraktar F; Yesil S
Endocr J; 2007 Aug; 54(4):593-9. PubMed ID: 17690487
[TBL] [Abstract][Full Text] [Related]
10. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
Chudý P; Kotuličová D; Staško J; Kubisz P
Blood Coagul Fibrinolysis; 2011 Sep; 22(6):493-8. PubMed ID: 21519232
[TBL] [Abstract][Full Text] [Related]
11. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.
Erem C; Nuhoglu I; Yilmaz M; Kocak M; Demirel A; Ucuncu O; Onder Ersoz H
J Endocrinol Invest; 2009 Feb; 32(2):169-74. PubMed ID: 19411818
[TBL] [Abstract][Full Text] [Related]
12. Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis.
Yener S; Akarsu M; Demir T; Akinci B; Sagol O; Bayraktar F; Ozcan MA; Tankurt E; Yesil S
J Endocrinol Invest; 2007 Nov; 30(10):810-9. PubMed ID: 18075282
[TBL] [Abstract][Full Text] [Related]
13. Fibrinolytic Changes in Women with Preeclampsia.
Godtfredsen AC; Sidelmann JJ; Dolleris BB; Jørgensen JS; Johansen EKJ; Pedersen MFB; Palarasah Y; Gram JB
Clin Appl Thromb Hemost; 2022; 28():10760296221126172. PubMed ID: 36217728
[TBL] [Abstract][Full Text] [Related]
14. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model.
Nagashima M; Werner M; Wang M; Zhao L; Light DR; Pagila R; Morser J; Verhallen P
Thromb Res; 2000 May; 98(4):333-42. PubMed ID: 10822080
[TBL] [Abstract][Full Text] [Related]
15. Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor.
Ridker PM; Vaughan DE; Stampfer MJ; Manson JE; Shen C; Newcomer LM; Goldhaber SZ; Hennekens CH
Circulation; 1992 May; 85(5):1822-7. PubMed ID: 1572039
[TBL] [Abstract][Full Text] [Related]
16. Assessment of fibrinolytic markers in patients with deep vein thrombosis.
Sharma S; Uppal V; Senee HK; Ahluwalia J; Das R; Varma N; Malhotra P; Kumar N
Blood Coagul Fibrinolysis; 2022 Mar; 33(2):113-118. PubMed ID: 35140191
[TBL] [Abstract][Full Text] [Related]
17. The hyperfibrinolytic state of mice with combined thrombin-activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor-1 gene deficiency is critically dependent on TAFI deficiency.
Vercauteren E; Peeters M; Hoylaerts MF; Lijnen HR; Meijers JC; Declerck PJ; Gils A
J Thromb Haemost; 2012 Dec; 10(12):2555-62. PubMed ID: 23083123
[TBL] [Abstract][Full Text] [Related]
18. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis.
van Tilburg NH; Rosendaal FR; Bertina RM
Blood; 2000 May; 95(9):2855-9. PubMed ID: 10779431
[TBL] [Abstract][Full Text] [Related]
19. Bispecific targeting of thrombin activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 by a heterodimer diabody.
Develter J; Booth NA; Declerck PJ; Gils A
J Thromb Haemost; 2008 Nov; 6(11):1884-91. PubMed ID: 18752580
[TBL] [Abstract][Full Text] [Related]
20. Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI.
Erem C; Nuhoglu I; Kocak M; Yilmaz M; Sipahi ST; Ucuncu O; Ersoz HO
Endocrine; 2008 Jun; 33(3):270-6. PubMed ID: 19016004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]